Literature DB >> 847296

Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.

A J Friedhoff, K Bonnet, H Tosengarten.   

Abstract

Rats treated chronically with dopamine receptor blockers were found to have an increase in striatal 3H-dopamine binding and adenylate cyclase activity as manifestations of receptor supersensitivity. Both the increase in binding and in adenylate cyclase activity were reversed by chronic 1-dopa treatment, presumably by increasing the supply of specific ligand (dopamine). The use of deliberate receptor sensitivity manipulation may be useful as a treatment for conditions involving disturbances in receptor sensitivity such as tardive dyskinesia and insulin resistant diabetes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 847296

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  17 in total

1.  Receptor mechanisms in increased sensitivity to serotonin agonists after dihydroxytryptamine shown by electronic monitoring of muscle twitches in the rat.

Authors:  R M Stewart; A Campbell; G Sperk; R J Baldessarini
Journal:  Psychopharmacology (Berl)       Date:  1979-02-28       Impact factor: 4.530

2.  L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.

Authors:  S Ferre; M Casas; A Cobos; C Garcia; F Jane; J M Grau
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Dopamine-receptor binding and adenylate-cyclase activity in mouse striatal tissue in the supersensitivity phase after neuroleptic treatment.

Authors:  J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1978-12-08       Impact factor: 4.530

Review 4.  Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

Authors:  P Muller; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

5.  Reduction of dopaminergic supersensitivity by a single dose of amphetamine.

Authors:  J L Haracz; L F Tseng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

6.  Levodopa and receptor sensitivity modification in tardive dyskinesia.

Authors:  D E Casey; J Gerlach; N Bjørndal
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.

Authors:  Y Clement-Cormier; C E Smith
Journal:  Neurochem Res       Date:  1980-06       Impact factor: 3.996

8.  Long-term depletion of histamine in guinea-pigs by administration of alpha-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase; effect on the sensitivity of histamine receptors.

Authors:  H Fukuda; K Maeyama; Y Ito; T Watanabe; H Wada
Journal:  Agents Actions       Date:  1988-06

9.  Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.

Authors:  M Toru; N Mataga; M Takashima; T Nishikawa
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.

Authors:  M Globus; J Bannet; B Lerer; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.